Ga naar de inhoud Ga naar de footer

Nieuws

All
General
Regulated
Transparency/Denominator

Nieuws, Regulated

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

Nieuws, Regulated

Oxurion ends discussions regarding previously announced preclinical transaction and continues integration of a strategic clinical partner

november 3, 2025

Nieuws, Regulated

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

oktober 23, 2025

Nieuws, Regulated

Oxurion Receives Amended Transparency Notifications from Atlas Special Opportunities II LLC

oktober 17, 2025

Nieuws, Regulated

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

oktober 16, 2025

Nieuws, Regulated

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

oktober 15, 2025

Nieuws, Regulated

Oxurion signs letter of intent for the contemplated acquisition of a CRO with strong complementarity to Axiodis

oktober 13, 2025

Nieuws, Regulated

Oxurion provides an update related to its investment strategy in digital assets

oktober 9, 2025

Nieuws, Regulated, Transparency/Denominator

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

oktober 3, 2025

Nieuws, Regulated

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

oktober 2, 2025

Nieuws, Regulated

Oxurion Publishes First Half 2025 Results

september 30, 2025

General, Nieuws

Axiodis CRO, the French subsidiary of the Oxurion Group, announces a dual AI-driven strategic initiative to transform clinical trials

september 16, 2025

Nieuws, Regulated

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

september 8, 2025

Nieuws, Regulated

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

september 1, 2025

Nieuws, Regulated

Oxurion confirms progress in negotiations related to its treasury diversification strategy; closing of the transaction expected before September 25, 2025

september 1, 2025

Nieuws, Regulated

Oxurion Receives Transparency Notifications from UBS Group AG

augustus 7, 2025

Nieuws, Regulated

Oxurion Ends R&D Program in Geographic Atrophy and Refocuses on New CRO Activities

augustus 7, 2025

Nieuws, Regulated

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

augustus 6, 2025

Nieuws, Regulated

Oxurion announces it obtained an improved indicative €30 million financing offer to initiate its plan to diversify by allocating part of its treasury into digital assets

augustus 4, 2025

General, Nieuws, Regulated

Oxurion completes the acquisition of Axiodis CRO and accelerates the structuring of its European clinical data platform

augustus 4, 2025

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

juni 25, 20250Opmerkingen

Oxurion signs a letter of intent for the planned acquisition of a preclinical microbiology CRO to diversify and strengthen its presence in the Toulouse region

juni 19, 20250Opmerkingen

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

juni 18, 20250Opmerkingen

Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities II LLC

juni 12, 20250Opmerkingen

Oxurion moves forward with the planned acquisition of Axiodis

juni 12, 20250Opmerkingen

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

juni 11, 20250Opmerkingen

First Supplement to the Prospectus dated 15 October 2024

juni 11, 20250Opmerkingen

First Supplement to the Prospectus dated 15 October 2024

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

juni 4, 20250Opmerkingen

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

juni 4, 20250Opmerkingen

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

mei 28, 20250Opmerkingen

Oxurion Announces Results on the Annual Shareholders’ Meeting of 13 May 2025

mei 22, 20250Opmerkingen

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

mei 20, 20250Opmerkingen

Oxurion announces the signing of a binding agreement to acquire French biometrics specialist Axiodis CRO

mei 16, 20250Opmerkingen

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

mei 15, 20250Opmerkingen

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

mei 12, 20250Opmerkingen

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

mei 9, 20250Opmerkingen

Oxurion announces that the transaction of July 2024 is stopped and confirms continuation of discussions regarding the acquisition project announced in March 2025

april 25, 20250Opmerkingen

2026-05-05 – Annual Shareholders Meeting

april 25, 20250Opmerkingen

2026-04-03 – Publication of the Annual Report

april 25, 20250Opmerkingen

2025-09-30 – Publication of the Half-year report

april 25, 20250Opmerkingen

Newest posts Older posts